Al­ny­lam touts la­bel ex­pan­sion for rare ox­alate dis­ease

Al­most two years af­ter se­cur­ing its third drug ap­proval, Al­ny­lam is tout­ing an ex­pand­ed la­bel for Oxlu­mo.

The com­pa­ny put out word on Thurs­day night that the FDA ap­proved an sN­DA for its treat­ment lumasir­an for pri­ma­ry hy­per­ox­aluria type 1, al­so known as Ph1. The rare ge­net­ic dis­ease, in which the body is un­able to reg­u­late the over­pro­duc­tion of ox­alate, can spur the de­vel­op­ment of kid­ney stones and play a role in lat­er-stage kid­ney dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.